AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Berenberg Bank

Berenberg Bank restated their buy rating on shares of AstraZeneca (LON:AZN) in a research note published on Monday morning, Marketbeat reports. The firm currently has a £150 ($197.24) target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on AZN. Jefferies Financial Group upped their price objective on AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the stock a hold rating in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reiterated a hold rating and issued a £110 ($144.64) price objective on shares of AstraZeneca in a report on Tuesday, June 18th. Shore Capital restated a buy rating on shares of AstraZeneca in a report on Thursday, July 25th. Citigroup restated a buy rating on shares of AstraZeneca in a report on Tuesday, May 28th. Finally, JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Tuesday, June 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has an average rating of Moderate Buy and a consensus price target of £105.53 ($138.77).

AstraZeneca Price Performance

AZN opened at £125.40 ($164.89) on Monday. The stock has a 50-day moving average price of £125.59 and a 200-day moving average price of £117.93. AstraZeneca has a 12-month low of GBX 9,461 ($124.40) and a 12-month high of £133.88 ($176.04). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The stock has a market capitalization of £194.37 billion, a P/E ratio of 4,019.23, a PEG ratio of 1.08 and a beta of 0.15.

AstraZeneca Cuts Dividend

The firm also recently declared a dividend, which will be paid on Monday, September 9th. Shareholders of record on Thursday, August 8th will be given a dividend of GBX 77.60 ($1.02) per share. This represents a yield of 0.64%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s payout ratio is 7,500.00%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.